Chris Harrington, Ph.D.
Dr. Harrington is Director of the Integrated Genomics Laboratory at OHSU. She has worked with RNA profiling and DNA variation analysis technologies throughout her research career. Her experience includes DNA microarrays, real-time PCR, and sequencing. At OHSU she initially set up and managed the Affymetrix microarray core in 2000 and has continued to expand resources and expertise for core users seeking services and support for high-throughput, genome-wide analyses of RNA and DNA. In addition to ongoing management of the Gene Profiling Shared Resource (GPSR), she oversees the OHSU Integrated Genomics Laboratory (IGL), a centralized laboratory home for next-generation sequencing, DNA microarray, high-throughput real-time PCR technologies and for RNA and DNA isolation support. The IGL coordinates services and infrastructure for the Gene Profiling Shared Resource, the Massively Parallel Sequencing Shared Resource, and the DNA Services Core. Prior to OHSU, Dr. Harrington was employed at Affymetrix from 1997 through October, 2000, as a Senior Staff Scientist and Manager of the Scientific Liaison Group. In this capacity she was involved in the development of the GeneChip array expression profiling application and was responsible for the Affymetrix Academic User Center, a program of research collaborations with academic investigators. Prior to her position at Affymetrix, Dr. Harrington worked in the field of molecular neurobiology, most recently as a Research Officer at the Garvan Institute for Medical Research, Sydney, Australia, and earlier as a Principal Research Fellow in the Laboratory for Molecular Pharmacology, University College, London, United Kingdom. Dr. Harrington has a PhD in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, and a BS in Biology from California Institute of Technology. In addition to overseeing the operation of the IGL and the GPSR, Dr. Harrington collaborates with many research groups on campus in the application of RNA and DNA analysis techniques to important questions in biomedical research. Recent publications include work examining cerebral spinal fluid for small RNA biomarkers of Alzheimer's disease (Lusardi et al., J Alzheimer's Disease, in 2016) and identification of gene expression changes that may provide diagnostic information for patients with inflammatory disease (Rosenbaum et al., JAMA Ophthalmology, 2015).